ABSTRACT
Bufexamac has caused many cases of sensitization, often with generalized eczematous eruptions, especially in Germany and Austria, where bufexamac-containing preparations were widely used. It is typically administered topically for treatment of subacute and chronic eczema of the skin, including atopic eczema and other inflammatory dermatoses, as well as sunburn and other minor burns, and itching. Problems of an allergic nature could have been anticipated: In France, in 1973, a trial of the treatment of various dermatoses with bufexamac cream and ointment was prematurely discontinued, as some 5% of the treated patients had developed symptoms highly suggestive of sensitization to bufexamac. As bufexamac was added to the baseline series by the IVDK in 1999, most studies performing routine tested have come from Germany, Austria and Switzerland; two such studies have been performed in Australia and France. It is uncertain whether all patients were tested with this hapten and the test concentration and vehicle were not mentioned.
